7 days or less is a rapid aHUS diagnosis
A rapid diagnosis of aHUS in 7 days or less usually results in the patient having the best of health outcomes…
Eculizumab biosimilars available in Europe and USA
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further…
Choice of aHUS treatments
In making a choice aHUS patients’ preferences among treatments like eculizumab (and its biosimulars) , ravulizumab, crovalimab, and iptacopan it largely…
Discontinuing complement inhibitor treatment
It is now just over 3 months since a discontinuing treatment decision making model was proposed to help aHUS patients make…
Out with old in with the new- not quite just yet
On the 10th anniversary of international aHUS awareness day it is timely to raise awareness that the old term aHUS is…
The first ever aHUS research study patient cohort
The Global Action website has been featuring the pioneers and first events of aHUS history in its series Before aHUS Endeavours…
The 2024 Global aHUS Poll
The 2024 Global aHUS Poll was closed to further responses on 18th July. It had been open for 6 weeks and…
Social media and aHUS- Before aHUS endeavours fade
aHUS in the social media is now much more commonplace. In this latest article in the series “Before aHUS Endeavours Fade”…
Atypical HUS and PNH: better together?
The diseases PNH and aHUS, although different, share features in common. Both are very rare, both are the result of uncontrolled…